雑誌文献を検索します。書籍を検索する際には「書籍検索」を選択してください。

検索

書誌情報 詳細検索 by 医中誌

Japanese

C5: Eculizumab Katsuichi Miyamoto 1 1Department of Neurology, Kinki University School of Medicine Keyword: エクリズマブ , 補体 , 分子標的薬 , 視神経脊髄炎 , 重症筋無力症 , eculizumab , complement , molecular targeted drugs , neuromyelitis optica , myasthenia gravis pp.1191-1199
Published Date 2014/10/1
DOI https://doi.org/10.11477/mf.1416200008
  • Abstract
  • Look Inside
  • Reference

Abstract

Eculizumab is a recombinant humanized monoclonal antibody that specifically binds to a C5 terminal complement and inhibits the cleavage of C5 to C5a and C5b through complement activation. Eculizumab has been used clinically for paroxysmal nocturnal hemoglobinuria. Clinical studies have been initiated for neurological disorders, such as, optic neuromyelitis and myasthenia gravis, mediated by the complement system. In addition, eculizumab is expected to be useful for the treatment of intractable neurological diseases.


Copyright © 2014, Igaku-Shoin Ltd. All rights reserved.

基本情報

電子版ISSN 1344-8129 印刷版ISSN 1881-6096 医学書院

関連文献

もっと見る

文献を共有